AbbVie Inc. ABBV
Healthcare · Drug Manufacturers - General · United States · S&P 500
Based on the available data, AbbVie Inc. gets an algorithmic score of 55/100. It trades at 263.29 $, with a bullish technical trend (RSI 55.0) and 26.4% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low beta (0.27): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 74.17 |
| Forward P/E | 16.18 |
| PEG | 0.54 |
| P/B | -78.38 |
| EV/EBITDA | 17.22 |
| P/S | 7.23 |
| ROA % | 10.51 |
| Gross margin % | 72.79 |
| Operating margin % | 40.03 |
| Net margin % | 9.80 |
| Revenue growth % (y/y) | 10.20 |
| Earnings growth % (y/y) | 290.40 |
| Revenue CAGR % | 1.75 |
| Earnings CAGR % | -29.06 |
| Current ratio | 0.81 |
| FCF yield % | 3.83 |
| Dividend yield % | 2.63 |
| Payout % | 190.40 |
Returns
| 1 month | +3.1 % |
| 3 months | +5.4 % |
| 6 months | +25.4 % |
| YTD | +17.5 % |
| 1 year | +23.1 % |
| 3 years | +91.2 % |
| 5 years | +195.2 % |
Risk
| 1-year volatility | 26.4 % |
| Beta | 0.27 |
| 5-year max drawdown | -21.9 % |
| Sharpe 1A | 0.77 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.